Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION PROTECT
2005-005592-14Phase 2Completed
- Sponsor
- IFS
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in optic neuritis (ON) and multiple sclerosis (MS) comparing Erypo + methylprednisolone with Placebo + methylprednisolone (2 arms). Primary endpoints: Retinal nerve fiber layer thickness change, Optic nerve head neural tissue volume change and 1 more. Started May 2006; status: completed.
02
Drugs
epoetin alfamethylprednisolone
03
Conditions
optic neuritis (ON)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-005592-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005592-14.